A Study of K-645 in the Treatment of Multiple Migraine Attacks

PHASE2RecruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

August 12, 2025

Primary Completion Date

May 31, 2026

Study Completion Date

May 31, 2026

Conditions
Acute Migraine
Interventions
DRUG

Placebo

Single oral dose of matching placebo

DRUG

K-645 dose level 1

Single oral dose of K-645 dose level 1

DRUG

K-645 dose level 2

Single oral dose of K-645 dose level 2

Trial Locations (18)

11235

RECRUITING

SPRI Clinical Trials, LLC, Brooklyn

14226

RECRUITING

Dent Neurosciences Research Center, Amherst

23606

RECRUITING

Health Research of Hampton Roads, Inc., Newport News

27260

RECRUITING

Peters Medical Research, High Point

27405

RECRUITING

Headache Wellness Center, Greensboro

30281

RECRUITING

Clinical Research Atlanta - Stockbridge, Stockbridge

30329

RECRUITING

DelRicht Research - Atlanta, Atlanta

37203

RECRUITING

Clinical Research Associates, Inc., Nashville

40213

RECRUITING

L-MARC Research Center, Louisville

55402

RECRUITING

Clinical Research Institute, Minneapolis

60657

RECRUITING

Chicago Headache Center and Research Institute, Chicago

66202

RECRUITING

Collective Medical Research, Overland Park

70817

RECRUITING

DelRicht Research - Prairieville, Prairieville

73034

RECRUITING

OK Clinical Research, LLC, Edmond

77081

RECRUITING

DM Clinical Research - Bellaire, Houston

77372

RECRUITING

APD Clinical Research, Splendora

87102

RECRUITING

Albuquerque Clinical Trials, Inc., Albuquerque

92056

RECRUITING

Excell Research, Inc., Oceanside

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Kallyope Inc.

INDUSTRY

NCT07116499 - A Study of K-645 in the Treatment of Multiple Migraine Attacks | Biotech Hunter | Biotech Hunter